Is NEUP or RANI more profitable?

Neuphoria Therapeutics' return on equity of -76.93% beat Rani Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Neuphoria Therapeutics N/A -76.93% -54.76% Rani Therapeutics N/A -206.46% -83.95%

Do analysts rate NEUP or AIFC?

Neuphoria Therapeutics currently has a consensus target price of $21.00, indicating a potential upside of 367.71%. Given Neuphoria Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Neuphoria Therapeutics is more favorable than ALT5 Sigma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neuphoria Therapeutics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 ALT5 Sigma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, NEUP or AIFC?

Neuphoria Therapeutics has higher earnings, but lower revenue than ALT5 Sigma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neuphoria Therapeutics -$13.27K -1,829.23 -$370K -$11.06 N/A ALT5 Sigma $24.84M 3.43 -$344.51M N/A N/A

Do analysts rate LIXT or NEUP?

Neuphoria Therapeutics has a consensus target price of $21.00, indicating a potential upside of 367.71%. Given Neuphoria Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Neuphoria Therapeutics is more favorable than Lixte Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lixte Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Neuphoria Therapeutics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is LIXT or NEUP more profitable?

Neuphoria Therapeutics' return on equity of -76.93% beat Lixte Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Lixte Biotechnology N/A -134.91% -95.61% Neuphoria Therapeutics N/A -76.93% -54.76%

Is NEUP or PMN more profitable?

Neuphoria Therapeutics' return on equity of -76.93% beat Promis Neurosciences' return on equity. Company Net Margins Return on Equity Return on Assets Neuphoria Therapeutics N/A -76.93% -54.76% Promis Neurosciences N/A -237.99% -151.04%

Neuphoria Therapeutics (NEUP) Competitors

$4.49 +0.13 (+2.98%)

Closing price 04:00 PM Eastern

Extended Trading

$4.34 -0.15 (-3.23%)

As of 05:32 PM Eastern

Compare

NEUP vs. RANI, ATRA, AIFC, LIXT, and PMN

Should you buy Neuphoria Therapeutics stock or one of its competitors? MarketBeat compares Neuphoria Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Neuphoria Therapeutics include Rani Therapeutics (RANI), Atara Biotherapeutics (ATRA), ALT5 Sigma (AIFC), Lixte Biotechnology (LIXT), and Promis Neurosciences (PMN). These companies are all part of the "pharmaceutical products" industry.

How does Neuphoria Therapeutics compare to Rani Therapeutics?

Neuphoria Therapeutics (NASDAQ:NEUP) and Rani Therapeutics (NASDAQ:RANI) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

Neuphoria Therapeutics has higher earnings, but lower revenue than Rani Therapeutics. Rani Therapeutics is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuphoria Therapeutics	-$13.27K	-1,829.23	-$370K	-$11.06	N/A
Rani Therapeutics	$3.17M	29.98	-$29.67M	-$0.41	N/A

Neuphoria Therapeutics has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market. Comparatively, Rani Therapeutics has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market.

Neuphoria Therapeutics presently has a consensus target price of $21.00, indicating a potential upside of 367.71%. Rani Therapeutics has a consensus target price of $8.75, indicating a potential upside of 1,040.81%. Given Rani Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Rani Therapeutics is more favorable than Neuphoria Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuphoria Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Neuphoria Therapeutics' return on equity of -76.93% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuphoria Therapeutics	N/A	-76.93%	-54.76%
Rani Therapeutics	N/A	-206.46%	-83.95%

15.9% of Neuphoria Therapeutics shares are owned by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are owned by institutional investors. 1.5% of Neuphoria Therapeutics shares are owned by insiders. Comparatively, 26.7% of Rani Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Neuphoria Therapeutics' average media sentiment score of 0.00 equaled Rani Therapeutics'average media sentiment score.

Company	Overall Sentiment
Neuphoria Therapeutics	Neutral
Rani Therapeutics	Neutral

Summary

Rani Therapeutics beats Neuphoria Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Neuphoria Therapeutics compare to Atara Biotherapeutics?

Atara Biotherapeutics (NASDAQ:ATRA) and Neuphoria Therapeutics (NASDAQ:NEUP) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability and analyst recommendations.

Atara Biotherapeutics has higher revenue and earnings than Neuphoria Therapeutics. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atara Biotherapeutics	$120.77M	0.79	$32.69M	-$0.67	N/A
Neuphoria Therapeutics	-$13.27K	-1,829.23	-$370K	-$11.06	N/A

70.9% of Atara Biotherapeutics shares are held by institutional investors. Comparatively, 15.9% of Neuphoria Therapeutics shares are held by institutional investors. 41.2% of Atara Biotherapeutics shares are held by company insiders. Comparatively, 1.5% of Neuphoria Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Atara Biotherapeutics has a beta of 0.11, suggesting that its stock price is 89% less volatile than the broader market. Comparatively, Neuphoria Therapeutics has a beta of 0.72, suggesting that its stock price is 28% less volatile than the broader market.

In the previous week, Atara Biotherapeutics' average media sentiment score of 0.00 equaled Neuphoria Therapeutics'average media sentiment score.

Company	Overall Sentiment
Atara Biotherapeutics	Neutral
Neuphoria Therapeutics	Neutral

Atara Biotherapeutics presently has a consensus price target of $9.50, suggesting a potential downside of 9.95%. Neuphoria Therapeutics has a consensus price target of $21.00, suggesting a potential upside of 367.71%. Given Neuphoria Therapeutics' higher possible upside, analysts plainly believe Neuphoria Therapeutics is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Neuphoria Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Neuphoria Therapeutics has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -40.91%. Neuphoria Therapeutics' return on equity of -76.93% beat Atara Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atara Biotherapeutics	-40.91%	-79.12%	-35.29%
Neuphoria Therapeutics	N/A	-76.93%	-54.76%

Summary

Atara Biotherapeutics beats Neuphoria Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Neuphoria Therapeutics compare to ALT5 Sigma?

Neuphoria Therapeutics (NASDAQ:NEUP) and ALT5 Sigma (NASDAQ:AIFC) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, media sentiment, earnings and analyst recommendations.

Neuphoria Therapeutics has higher earnings, but lower revenue than ALT5 Sigma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuphoria Therapeutics	-$13.27K	-1,829.23	-$370K	-$11.06	N/A
ALT5 Sigma	$24.84M	3.43	-$344.51M	N/A	N/A

In the previous week, Neuphoria Therapeutics' average media sentiment score of 0.00 equaled ALT5 Sigma'saverage media sentiment score.

Company	Overall Sentiment
Neuphoria Therapeutics	Neutral
ALT5 Sigma	Neutral

Neuphoria Therapeutics currently has a consensus target price of $21.00, indicating a potential upside of 367.71%. Given Neuphoria Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Neuphoria Therapeutics is more favorable than ALT5 Sigma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuphoria Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ALT5 Sigma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Neuphoria Therapeutics has a net margin of 0.00% compared to ALT5 Sigma's net margin of -2,483.94%. ALT5 Sigma's return on equity of -68.25% beat Neuphoria Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuphoria Therapeutics	N/A	-76.93%	-54.76%
ALT5 Sigma	-2,483.94%	-68.25%	-62.43%

Neuphoria Therapeutics has a beta of 0.72, meaning that its share price is 28% less volatile than the broader market. Comparatively, ALT5 Sigma has a beta of 1.71, meaning that its share price is 71% more volatile than the broader market.

15.9% of Neuphoria Therapeutics shares are owned by institutional investors. Comparatively, 6.3% of ALT5 Sigma shares are owned by institutional investors. 1.5% of Neuphoria Therapeutics shares are owned by company insiders. Comparatively, 0.2% of ALT5 Sigma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Neuphoria Therapeutics beats ALT5 Sigma on 8 of the 12 factors compared between the two stocks.

How does Neuphoria Therapeutics compare to Lixte Biotechnology?

Lixte Biotechnology (NASDAQ:LIXT) and Neuphoria Therapeutics (NASDAQ:NEUP) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.

Lixte Biotechnology has a beta of 1.27, suggesting that its stock price is 27% more volatile than the broader market. Comparatively, Neuphoria Therapeutics has a beta of 0.72, suggesting that its stock price is 28% less volatile than the broader market.

Neuphoria Therapeutics has lower revenue, but higher earnings than Lixte Biotechnology. Lixte Biotechnology is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lixte Biotechnology	N/A	N/A	-$6.01M	-$1.13	N/A
Neuphoria Therapeutics	-$13.27K	-1,829.23	-$370K	-$11.06	N/A

Neuphoria Therapeutics' return on equity of -76.93% beat Lixte Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lixte Biotechnology	N/A	-134.91%	-95.61%
Neuphoria Therapeutics	N/A	-76.93%	-54.76%

In the previous week, Lixte Biotechnology had 1 more articles in the media than Neuphoria Therapeutics. MarketBeat recorded 1 mentions for Lixte Biotechnology and 0 mentions for Neuphoria Therapeutics. Lixte Biotechnology's average media sentiment score of 0.00 equaled Neuphoria Therapeutics'average media sentiment score.

Company	Overall Sentiment
Lixte Biotechnology	Neutral
Neuphoria Therapeutics	Neutral

5.1% of Lixte Biotechnology shares are owned by institutional investors. Comparatively, 15.9% of Neuphoria Therapeutics shares are owned by institutional investors. 9.5% of Lixte Biotechnology shares are owned by insiders. Comparatively, 1.5% of Neuphoria Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Neuphoria Therapeutics has a consensus target price of $21.00, indicating a potential upside of 367.71%. Given Neuphoria Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Neuphoria Therapeutics is more favorable than Lixte Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lixte Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Neuphoria Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Neuphoria Therapeutics beats Lixte Biotechnology on 8 of the 13 factors compared between the two stocks.

How does Neuphoria Therapeutics compare to Promis Neurosciences?

Neuphoria Therapeutics (NASDAQ:NEUP) and Promis Neurosciences (NASDAQ:PMN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.

Neuphoria Therapeutics currently has a consensus target price of $21.00, suggesting a potential upside of 367.71%. Promis Neurosciences has a consensus target price of $26.50, suggesting a potential upside of 158.79%. Given Neuphoria Therapeutics' higher possible upside, analysts clearly believe Neuphoria Therapeutics is more favorable than Promis Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuphoria Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Promis Neurosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

15.9% of Neuphoria Therapeutics shares are owned by institutional investors. Comparatively, 50.1% of Promis Neurosciences shares are owned by institutional investors. 1.5% of Neuphoria Therapeutics shares are owned by company insiders. Comparatively, 1.5% of Promis Neurosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Promis Neurosciences had 3 more articles in the media than Neuphoria Therapeutics. MarketBeat recorded 3 mentions for Promis Neurosciences and 0 mentions for Neuphoria Therapeutics. Neuphoria Therapeutics' average media sentiment score of 0.00 equaled Promis Neurosciences'average media sentiment score.

Company	Overall Sentiment
Neuphoria Therapeutics	Neutral
Promis Neurosciences	Neutral

Neuphoria Therapeutics' return on equity of -76.93% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuphoria Therapeutics	N/A	-76.93%	-54.76%
Promis Neurosciences	N/A	-237.99%	-151.04%

Neuphoria Therapeutics has a beta of 0.72, meaning that its share price is 28% less volatile than the broader market. Comparatively, Promis Neurosciences has a beta of -0.19, meaning that its share price is 119% less volatile than the broader market.

Neuphoria Therapeutics has higher earnings, but lower revenue than Promis Neurosciences. Promis Neurosciences is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuphoria Therapeutics	-$13.27K	-1,829.23	-$370K	-$11.06	N/A
Promis Neurosciences	N/A	N/A	-$39.72M	-$14.51	N/A

Summary

Neuphoria Therapeutics beats Promis Neurosciences on 7 of the 13 factors compared between the two stocks.

Get Neuphoria Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NEUP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NEUP vs. The Competition

Export

Metric	Neuphoria Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$24.27M	$3.51B	$6.56B	$12.24B
Dividend Yield	N/A	2.30%	2.69%	5.82%
P/E Ratio	-0.41	20.68	25.17	23.98
Price / Sales	-1,829.23	336.69	553.76	120.62
Price / Cash	28.49	128.56	44.82	54.51
Price / Book	0.44	8.26	10.76	6.41
Net Income	-$370K	$23.91M	$3.56B	$337.14M
7 Day Performance	4.18%	3.05%	1.37%	-0.48%
1 Month Performance	-18.07%	2.40%	0.81%	0.49%
1 Year Performance	-27.58%	56.35%	30.53%	28.16%

Neuphoria Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NEUP Neuphoria Therapeutics	2.6686 of 5 stars	$4.49 +3.0%	$21.00 +367.7%	-27.9%	$24.27M	-$13.27K	N/A	N/A
RANI Rani Therapeutics	2.4356 of 5 stars	$0.76 -5.2%	$8.75 +1,051.2%	+54.1%	$94.16M	$1.63M	N/A	110	Gap Up
ATRA Atara Biotherapeutics	1.0483 of 5 stars	$10.41 -0.5%	$9.50 -8.7%	+41.6%	$93.80M	$120.77M	N/A	330
AIFC ALT5 Sigma	0.0759 of 5 stars	$0.66 +0.5%	N/A	-92.9%	$92.98M	$24.70M	N/A	170	News Coverage
LIXT Lixte Biotechnology	0.177 of 5 stars	$6.19 -14.6%	N/A	+826.9%	$92.97M	N/A	N/A	4	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NEUP) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Neuphoria Therapeutics (NEUP) Competitors

NEUP vs. RANI, ATRA, AIFC, LIXT, and PMN

How does Neuphoria Therapeutics compare to Rani Therapeutics?

Summary

How does Neuphoria Therapeutics compare to Atara Biotherapeutics?

Summary

How does Neuphoria Therapeutics compare to ALT5 Sigma?

Summary

How does Neuphoria Therapeutics compare to Lixte Biotechnology?

Summary

How does Neuphoria Therapeutics compare to Promis Neurosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NEUP vs. The Competition

Neuphoria Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Neuphoria Therapeutics (NEUP) Competitors

NEUP vs. RANI, ATRA, AIFC, LIXT, and PMN

How does Neuphoria Therapeutics compare to Rani Therapeutics?

Which has better valuation and earnings, NEUP or RANI?

Which has more volatility and risk, NEUP or RANI?

Do analysts rate NEUP or RANI?

Is NEUP or RANI more profitable?

Do insiders & institutionals believe in NEUP or RANI?

Does the media refer more to NEUP or RANI?

Summary

How does Neuphoria Therapeutics compare to Atara Biotherapeutics?

Which has higher valuation & earnings, ATRA or NEUP?

Do institutionals and insiders believe in ATRA or NEUP?

Which has more volatility and risk, ATRA or NEUP?

Does the media refer more to ATRA or NEUP?

Do analysts recommend ATRA or NEUP?

Is ATRA or NEUP more profitable?

Summary

How does Neuphoria Therapeutics compare to ALT5 Sigma?

Which has higher earnings & valuation, NEUP or AIFC?

Does the media favor NEUP or AIFC?

Do analysts rate NEUP or AIFC?

Is NEUP or AIFC more profitable?

Which has more volatility & risk, NEUP or AIFC?

Do institutionals and insiders believe in NEUP or AIFC?

Summary

How does Neuphoria Therapeutics compare to Lixte Biotechnology?

Which has more risk and volatility, LIXT or NEUP?

Which has higher valuation and earnings, LIXT or NEUP?

Is LIXT or NEUP more profitable?

Does the media refer more to LIXT or NEUP?

Do institutionals and insiders believe in LIXT or NEUP?

Do analysts rate LIXT or NEUP?

Summary

How does Neuphoria Therapeutics compare to Promis Neurosciences?

Do analysts rate NEUP or PMN?

Do insiders and institutionals have more ownership in NEUP or PMN?

Does the media favor NEUP or PMN?

Is NEUP or PMN more profitable?

Which has more risk & volatility, NEUP or PMN?

Which has higher earnings and valuation, NEUP or PMN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NEUP vs. The Competition

Neuphoria Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools